Fund Holdings — ACORN CAPITAL ADVISORS, LLC

Total Portfolio Value:
$149.95M
Total Bought:
$25.43M
Total Sold:
$4.13M
Net Transaction:
+$21.30M
Securities
▲▼
SharesValue
Q4 2024
▲▼
Q1 2025
▲▼
Change
▲▼
Q4 2024
▲▼
Q1 2025
▲▼
Weight (%)
▲▼
Change
▲▼
CG Oncology, Inc.(CGON)1,131,5011,131,5010$32.45M$27.72M18.49%-$4.73M
UroGen Pharma Ltd.(URGN)1,516,3031,516,3030$16.15M$16.77M11.18%+$621.7K
Y-Mabs Therapeutics Inc2,861,8253,235,387+373,562$22.41M$14.33M9.56%-$8.08M
Trevi Therapeutics, Inc.(TRVI)2,001,0482,144,844+143,796$8.24M$13.49M9.00%+$5.25M
Candel Therapeutics, Inc.(CADL)1,939,6442,152,252+212,608$16.84M$12.16M8.11%-$4.68M
Puma Biotechnology, Inc.(PBYI)3,940,0523,940,0520$12.02M$11.66M7.78%-$354.6K
Bicara Therapeutics643,381643,382+1$11.21M$8.38M5.59%-$2.82M
Protara Therapeutics, Inc.(TARA)1,279,8001,279,8000$6.76M$5.45M3.64%-$1.31M
Terns Pharmaceuticals Inc1,971,2641,971,2640$10.92M$5.44M3.63%-$5.48M
OnKure Therapeutics, Inc.CL A(OKUR)1,439,6741,439,6740$10.25M$5.12M3.42%-$5.12M
Verastem, Inc.(VSTM)779,498779,4980$779.5K$4.70M3.13%+$3.92M
Cybin D/B/A Helus Pharma(HELP)734,393734,394+1$6.48M$4.66M3.11%-$1.81M
Cardiff Oncology, Inc.(CRDF)1,442,3081,442,3080$6.26M$4.53M3.02%-$1.73M
Optinose Inc422,813422,814+1$2.82M$3.88M2.59%+$1.05M
Whitehawk Therapeutics, Inc.(WHWK)1,147,0521,139,363-7,689$3.62M$2.03M1.35%-$1.59M
X4 Pharmaceuticals, Inc.(XFOR)7,310,6507,310,6500$5.36M$1.75M1.17%-$3.61M
Mural Oncology Plc1,286,0791,269,715-16,364$4.14M$1.60M1.07%-$2.54M
Aura Biosciences, Inc.(AURA)0590,508+590,508$0$1.45M0.97%+$1.45M
BioAtla, Inc.(BCAB)4,032,0464,032,0460$2.38M$1.41M0.94%-$972.5K
Q32 Bio Inc.(QTTB)803,425803,4250$2.76M$1.33M0.88%-$1.44M
Yarrow Bioscience Inc(YARW)456,970785,938+328,968$1.53M$1.24M0.83%-$289.1K
Acrivon Therapeutics Inc405,237405,2370$2.44M$822.6K0.55%-$1.62M
Page 1 of 1
ACORN CAPITAL ADVISORS, LLC — 13F Holdings — Q1 2025 | TickerTrail